Effects of intravenous amiodarone in patients with inducible repetitive ventricular responses and ventricular tachycardia

Hariman, Robert J.; Gomes, J. Anthony; Kang, Pritpal S.; El‐Sherif, Nabil

doi:10.1016/0002-8703(84)90265-5

Cited by 30 publications

(1 citation statement)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…34 In addition, 5 of 6 AMI patients treated with intravenous amiodarone developed refractory VT. 18 One of the reasons why Purkinje networkmediated arrhythmias are refractory to intravenous amiodarone may be the weak effect of amiodarone on refractoriness of the His-Purkinje system. 35 Therefore, in cases of refractory VT/VF for electrical defibrillation/cardioversion and antiarrhythmic agents, sedation and ECMO support should be on hand for termination of VT/VF and hemodynamic stabilization.…”

Section: Irb Informationmentioning

confidence: 99%

Incidence, Predictors, and Outcome Associated With Ventricular Tachycardia or Fibrillation in Patients Undergoing Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction

Hanada,

Kinjo,

Yokoyama

et al. 2024

Circ J

View full text Add to dashboard Cite

Background:The characteristics and clinical outcomes associated with sustained ventricular tachycardia and fibrillation (VT/VF) in Japanese acute myocardial infarction (AMI) patients remain unknown. Methods and Results:Consecutive AMI patients (n=1,941) transferred to the Hirosaki University Hospital and treated with primary percutaneous coronary intervention (PCI) within 12 h of onset were retrospectively studied. The incidence of VT/VF during hospitalization was 8.3%, and 75% of cases occurred by the end of PCI. Independent predictors associated with VT/VF occurrence by the end of PCI and after PCI, respectively, were identified. Additionally, the differences between patients with VT and VF were examined, which revealed that the characteristics of patients and predictors for VT and VF were clearly different. Additionally, the QRS duration during VT was measured, which demonstrated the possible involvement of Purkinje fibers for VT in the acute phase of AMI. Of the patients with VT/VF, 12% required ECMO support due to refractory VT/VF despite intravenous antiarrhythmic agents such as β-blockers, amiodarone, and nifekalant. Among the patients discharged alive, 1,690 were followed up for a mean of 3.7 years. VT/VF occurrence during hospitalization did not affect the mid-term clinical outcomes even in patients with VT. Conclusions:The results clearly indicated that VT/VF is still a serious complications of AMI. We need to identify patients at high risk of developing VT/VF for careful observation and appropriate intervention.

show abstract

Section: Irb Informationmentioning

confidence: 99%